Pub Date : 2024-05-01DOI: 10.21608/nrmj.2024.280135.1508
Mohammed Ajdig, Bahia Rached, Ahlam Mbarki, T. Chouati, C. Talbi, Elmostafa El Fahime, M. Melloul
Bacillus paralicheniformis is a new identified species, which was distinguished from Bacillus licheniformis in 2015 through extensive phylogenomic and phylogenetic analyses. In this context, this study aimed to achieve a clear identification of the active plant-growth promoting rhizobacteria (PGPR) B. paralicheniformis isolates among the closely related B. licheniformis through molecular typing, helping for the development of clearly-identified PGPR isolates to be used as biofertilizers. A total of 15 rhizobacteria were isolated from the olive rhizosphere
{"title":"Use of rpoB gene phylogenetic marker-based distinction of abiotic stress tolerant and plant-growth promoting Bacillus paralicheniformis isolates from their closely related Bacillus licheniformis","authors":"Mohammed Ajdig, Bahia Rached, Ahlam Mbarki, T. Chouati, C. Talbi, Elmostafa El Fahime, M. Melloul","doi":"10.21608/nrmj.2024.280135.1508","DOIUrl":"https://doi.org/10.21608/nrmj.2024.280135.1508","url":null,"abstract":"Bacillus paralicheniformis is a new identified species, which was distinguished from Bacillus licheniformis in 2015 through extensive phylogenomic and phylogenetic analyses. In this context, this study aimed to achieve a clear identification of the active plant-growth promoting rhizobacteria (PGPR) B. paralicheniformis isolates among the closely related B. licheniformis through molecular typing, helping for the development of clearly-identified PGPR isolates to be used as biofertilizers. A total of 15 rhizobacteria were isolated from the olive rhizosphere","PeriodicalId":34593,"journal":{"name":"Novel Research in Microbiology Journal","volume":"116 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141035056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-03-22DOI: 10.21608/nrmj.2024.273319.1479
Gopinath R., Arundadhi M., Dhanasezhian A., Thangam G. Sucila
The Gut-Brain Axis is a complex and fascinating concept elucidating the two-way communication between gut microbiota and the central nervous system, encompassing diverse mechanisms with profound implications on neurological health. Situated in the gastrointestinal tract, the gut microbiota, a diverse bacterial community, which communicates with the brain through various processes, including neurotransmitter and neuropeptide synthesis, immune system modulation, and involvement of the vagus nerve. These interactions not only impact digestion but also influence emotions, cognition, and behavior. Recent research has revealed the significant influence of gut microbiota on the neurological health, establishing connections between alterations in the gut microbiota composition and the prevailing conditions such as depression and neurodegenerative diseases. This understanding sheds new light on the pathophysiology of neurological disorders, marking the gut-brain axis as an exciting frontier in neuroscience and medicine. The aims of this study were to investigate and elucidate the intricate interplay between the gut microbiota and neurological health, and exploring the mechanisms of communication along the gut-brain axis. As research progresses, the potential for groundbreaking strategies to prevent and treat the neurological disorders becomes increasingly apparent. This comprehensive review delves into the nuanced world of the gut-brain axis, providing insights into the intricate relationship between the gut and the brain. Additionally, this review delves into potential therapeutic implications, exploring the use of probiotics, prebiotics, and dietary interventions to modulate gut microbiota for enhancement of the neurological well-being.
{"title":"From gut to brain: Deciphering the impact of gut microbiota on neurological health","authors":"Gopinath R., Arundadhi M., Dhanasezhian A., Thangam G. Sucila","doi":"10.21608/nrmj.2024.273319.1479","DOIUrl":"https://doi.org/10.21608/nrmj.2024.273319.1479","url":null,"abstract":"The Gut-Brain Axis is a complex and fascinating concept elucidating the two-way communication between gut microbiota and the central nervous system, encompassing diverse mechanisms with profound implications on neurological health. Situated in the gastrointestinal tract, the gut microbiota, a diverse bacterial community, which communicates with the brain through various processes, including neurotransmitter and neuropeptide synthesis, immune system modulation, and involvement of the vagus nerve. These interactions not only impact digestion but also influence emotions, cognition, and behavior. Recent research has revealed the significant influence of gut microbiota on the neurological health, establishing connections between alterations in the gut microbiota composition and the prevailing conditions such as depression and neurodegenerative diseases. This understanding sheds new light on the pathophysiology of neurological disorders, marking the gut-brain axis as an exciting frontier in neuroscience and medicine. The aims of this study were to investigate and elucidate the intricate interplay between the gut microbiota and neurological health, and exploring the mechanisms of communication along the gut-brain axis. As research progresses, the potential for groundbreaking strategies to prevent and treat the neurological disorders becomes increasingly apparent. This comprehensive review delves into the nuanced world of the gut-brain axis, providing insights into the intricate relationship between the gut and the brain. Additionally, this review delves into potential therapeutic implications, exploring the use of probiotics, prebiotics, and dietary interventions to modulate gut microbiota for enhancement of the neurological well-being.","PeriodicalId":34593,"journal":{"name":"Novel Research in Microbiology Journal","volume":"99 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140386982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-21DOI: 10.21608/nrmj.2024.264515.1425
Gehad M. Mohamed, Ahmed B. Barakat, Marwa M. Gado, Fatma M. Abdallah
Approximately 71 million people worldwide are supposed to have chronic hepatitis C virus (CHCV). New direct-acting antiviral (DAA) medications have been used, which helped successfully in complete treatment of CHCV and achieved a sustained virological response (SVR). However, some patients may acquire HCV resistance to DAAs, which may result in treatments failure. The aim of the present study was to compare among the patients that were experiencing virologic relapse (VR) and SVR in relation to the patterns of NS5A and NS5B genes resistance associated substitutions (RASs) in the chronic HCV infected Egyptian patients, who received Sofosbuvir (SOF) and Daclatasvir (DCV) combination therapy. All patients that were infected by chronic HCV had completed treatment with SOF and DCV combination therapy and were followed up after the end of this treatment. A total of 10 out of 100 serum specimens were collected from the enrolled patients and analyzed, where two and eight specimens were representatives for VR and SVR, respectively. These samples had undergone reverse transcriptase-polymerase chain reaction amplification (RT-PCR) of NS5A and NS5B genes, partially sequenced by the Sanger method, and then analyzed phylogenetically to determine their genetic subtypes and RASs. Finally, SVR was gained in all but two patients who were experiencing VR that carried natural NS5A -RASs at positions L31M and Y93H. They were considered as significant for DCV resistance as well as natural NS5B -RASs (T282S), which represented the main polymorphism for SOF resistance. In this study, a number of mutational combinations in the analyzed NS5A and NS5B genes were identified, which may increase the risk of treatments failure in the patients administered regimens including multiple DAA, compared to the baseline sequences of those patients that were experiencing SVR.
{"title":"Association of multiple mutations in NS5A and NS5B genes and resistance to direct-acting antivirals in chronically infected Egyptian patients with Hepatitis C virus Genotype 4a","authors":"Gehad M. Mohamed, Ahmed B. Barakat, Marwa M. Gado, Fatma M. Abdallah","doi":"10.21608/nrmj.2024.264515.1425","DOIUrl":"https://doi.org/10.21608/nrmj.2024.264515.1425","url":null,"abstract":"Approximately 71 million people worldwide are supposed to have chronic hepatitis C virus (CHCV). New direct-acting antiviral (DAA) medications have been used, which helped successfully in complete treatment of CHCV and achieved a sustained virological response (SVR). However, some patients may acquire HCV resistance to DAAs, which may result in treatments failure. The aim of the present study was to compare among the patients that were experiencing virologic relapse (VR) and SVR in relation to the patterns of NS5A and NS5B genes resistance associated substitutions (RASs) in the chronic HCV infected Egyptian patients, who received Sofosbuvir (SOF) and Daclatasvir (DCV) combination therapy. All patients that were infected by chronic HCV had completed treatment with SOF and DCV combination therapy and were followed up after the end of this treatment. A total of 10 out of 100 serum specimens were collected from the enrolled patients and analyzed, where two and eight specimens were representatives for VR and SVR, respectively. These samples had undergone reverse transcriptase-polymerase chain reaction amplification (RT-PCR) of NS5A and NS5B genes, partially sequenced by the Sanger method, and then analyzed phylogenetically to determine their genetic subtypes and RASs. Finally, SVR was gained in all but two patients who were experiencing VR that carried natural NS5A -RASs at positions L31M and Y93H. They were considered as significant for DCV resistance as well as natural NS5B -RASs (T282S), which represented the main polymorphism for SOF resistance. In this study, a number of mutational combinations in the analyzed NS5A and NS5B genes were identified, which may increase the risk of treatments failure in the patients administered regimens including multiple DAA, compared to the baseline sequences of those patients that were experiencing SVR.","PeriodicalId":34593,"journal":{"name":"Novel Research in Microbiology Journal","volume":"93 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140444144","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-04DOI: 10.21608/nrmj.2024.339900
Ghadir A. El-Chaghaby, Heba A. Shehta, S. Rashad, El-Shaimaa A. Rawash, Heba R. Eid
{"title":"Evaluation of the antioxidant and antimicrobial activities of the spent coffee extracts and their applications as natural food preservatives of chicken fillets","authors":"Ghadir A. El-Chaghaby, Heba A. Shehta, S. Rashad, El-Shaimaa A. Rawash, Heba R. Eid","doi":"10.21608/nrmj.2024.339900","DOIUrl":"https://doi.org/10.21608/nrmj.2024.339900","url":null,"abstract":"","PeriodicalId":34593,"journal":{"name":"Novel Research in Microbiology Journal","volume":"91 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139806886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-02-04DOI: 10.21608/nrmj.2024.339900
Ghadir A. El-Chaghaby, Heba A. Shehta, S. Rashad, El-Shaimaa A. Rawash, Heba R. Eid
{"title":"Evaluation of the antioxidant and antimicrobial activities of the spent coffee extracts and their applications as natural food preservatives of chicken fillets","authors":"Ghadir A. El-Chaghaby, Heba A. Shehta, S. Rashad, El-Shaimaa A. Rawash, Heba R. Eid","doi":"10.21608/nrmj.2024.339900","DOIUrl":"https://doi.org/10.21608/nrmj.2024.339900","url":null,"abstract":"","PeriodicalId":34593,"journal":{"name":"Novel Research in Microbiology Journal","volume":"37 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139866621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-17DOI: 10.21608/nrmj.2024.336939
Sara A. Alshaikh, T. El-Banna, F. Sonbol, Mahmoud H. Farghali
Uropathogenic Escherichia coli (UPEC) is the primary etiologic agent of urinary tract infections (UTIs). This study aimed to investigate the difference in antimicrobial susceptibility of UPEC isolates in the planktonic and biofilm states. Important virulence factors were also evaluated. The minimum inhibitory concentrations (MICs) were determined and recorded as 0.5-64 μg/ ml for amikacin, 0.5-64 μg/ ml for cefotaxime, 0.25-64 μg/ ml for cefepime, 0.25-16 μg/ ml for meropenem, and 0.125-32 μg/ ml for ciprofloxacin. Biofilm-specific resistance was assessed using the minimum biofilm eradication concentration (MBEC). The obtained results for MBEC were: 8-512 μg/ ml for amikacin, 32-512 μg/ ml for cefotaxime, 8-512 μg/ ml for cefepime, 4-256 μg/ ml for meropenem, and 4-128 μg/ ml for ciprofloxacin. The virulence factors were evaluated using suitable phenotypic techniques. Our findings revealed a significant enhancement in the antimicrobial resistance after biofilm formation. The MBEC values were higher than the MIC values by 2-128 folds for amikacin, 2-256 folds for cefotaxime, 2-64 folds for cefepime, 8-128 folds for meropenem, and 4-128 folds for ciprofloxacin. The swimming and swarming motilities demonstrated a significant positive correlation ( rs = 0.506, P < 0.001). Protease production analysis revealed a large variation, with the weak biofilm-producing isolates EW2 and EW15 displaying the largest zone diameters of 39 mm and 33 mm; respectively. We have also evaluated the distribution and levels of siderophore production, which were significantly associated with meropenem resistance. Finally, this study underscores the importance of considering biofilm formation in UPEC treatment and emphasizes the need for therapeutics targeting these biofilms.
{"title":"In-vitro investigation of biofilm-specific resistance and virulence of biofilm-forming uropathogenic Escherichia coli","authors":"Sara A. Alshaikh, T. El-Banna, F. Sonbol, Mahmoud H. Farghali","doi":"10.21608/nrmj.2024.336939","DOIUrl":"https://doi.org/10.21608/nrmj.2024.336939","url":null,"abstract":"Uropathogenic Escherichia coli (UPEC) is the primary etiologic agent of urinary tract infections (UTIs). This study aimed to investigate the difference in antimicrobial susceptibility of UPEC isolates in the planktonic and biofilm states. Important virulence factors were also evaluated. The minimum inhibitory concentrations (MICs) were determined and recorded as 0.5-64 μg/ ml for amikacin, 0.5-64 μg/ ml for cefotaxime, 0.25-64 μg/ ml for cefepime, 0.25-16 μg/ ml for meropenem, and 0.125-32 μg/ ml for ciprofloxacin. Biofilm-specific resistance was assessed using the minimum biofilm eradication concentration (MBEC). The obtained results for MBEC were: 8-512 μg/ ml for amikacin, 32-512 μg/ ml for cefotaxime, 8-512 μg/ ml for cefepime, 4-256 μg/ ml for meropenem, and 4-128 μg/ ml for ciprofloxacin. The virulence factors were evaluated using suitable phenotypic techniques. Our findings revealed a significant enhancement in the antimicrobial resistance after biofilm formation. The MBEC values were higher than the MIC values by 2-128 folds for amikacin, 2-256 folds for cefotaxime, 2-64 folds for cefepime, 8-128 folds for meropenem, and 4-128 folds for ciprofloxacin. The swimming and swarming motilities demonstrated a significant positive correlation ( rs = 0.506, P < 0.001). Protease production analysis revealed a large variation, with the weak biofilm-producing isolates EW2 and EW15 displaying the largest zone diameters of 39 mm and 33 mm; respectively. We have also evaluated the distribution and levels of siderophore production, which were significantly associated with meropenem resistance. Finally, this study underscores the importance of considering biofilm formation in UPEC treatment and emphasizes the need for therapeutics targeting these biofilms.","PeriodicalId":34593,"journal":{"name":"Novel Research in Microbiology Journal","volume":"9 13","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139616530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-01-01DOI: 10.21608/nrmj.2024.336571
Syeda Sadaf Wajahat
About 70 % of the surface of Earth is covered with oceans and hosts an enormous variety of environmental, biological, and chemical standings. The marine environment consists of a comprehensive range of animals, plants, and microorganisms, which have several benefits in the biotechnological developments. This review aimed to investigate the potentials of using the marine microbial enzymes in therapeutics. The marine microbial species were uncultivable but recently, scientists cultivated certain seawater microbes effectively by a metagenomic technique. Several studies on the marine microbiome are undergoing and it can be assumed that approximately 91 % of the microbial species in the oceans are unidentified. The marine surroundings possess an exclusive environment with inimitable features and become a source of microbes fabricating many biocatalysts with no earthbound analog. The oceanic microbial enzymes have recently been found to be eco-friendly, rapid, inexpensive for construction, and can be used in several industries, including food, fabric, cleansers, medications, chemicals, dairy, biodiesel, and cosmetics. Compared with the mesophilic enzymes, the extremozymes execute a wider range of reactions and can act as natural substitutes for the mesophilic enzymes. The most relevant part of the worldwide economy is the therapeutic industry, whose market value is around 1.1 trillion US $. The enzyme biocatalysis is a prevailing approach that can be implemented in an assortment of industries, and is a more discriminative tool, sustainable, and eco-friendly as compared with the chemical catalysis.
{"title":"Potentials of the marine microbial enzymes in therapeutics","authors":"Syeda Sadaf Wajahat","doi":"10.21608/nrmj.2024.336571","DOIUrl":"https://doi.org/10.21608/nrmj.2024.336571","url":null,"abstract":"About 70 % of the surface of Earth is covered with oceans and hosts an enormous variety of environmental, biological, and chemical standings. The marine environment consists of a comprehensive range of animals, plants, and microorganisms, which have several benefits in the biotechnological developments. This review aimed to investigate the potentials of using the marine microbial enzymes in therapeutics. The marine microbial species were uncultivable but recently, scientists cultivated certain seawater microbes effectively by a metagenomic technique. Several studies on the marine microbiome are undergoing and it can be assumed that approximately 91 % of the microbial species in the oceans are unidentified. The marine surroundings possess an exclusive environment with inimitable features and become a source of microbes fabricating many biocatalysts with no earthbound analog. The oceanic microbial enzymes have recently been found to be eco-friendly, rapid, inexpensive for construction, and can be used in several industries, including food, fabric, cleansers, medications, chemicals, dairy, biodiesel, and cosmetics. Compared with the mesophilic enzymes, the extremozymes execute a wider range of reactions and can act as natural substitutes for the mesophilic enzymes. The most relevant part of the worldwide economy is the therapeutic industry, whose market value is around 1.1 trillion US $. The enzyme biocatalysis is a prevailing approach that can be implemented in an assortment of industries, and is a more discriminative tool, sustainable, and eco-friendly as compared with the chemical catalysis.","PeriodicalId":34593,"journal":{"name":"Novel Research in Microbiology Journal","volume":"16 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140517563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-24DOI: 10.21608/nrmj.2023.327188
Dmitriy V. Alekseev, Artem V. Lyamin, Karim A. Kayumov
Cystic fibrosis (CF) is one of the most common genetic disorders; resulting in a wide variety of complications, including respiratory infections. Such infections are often ineffectively treated within the framework of a classical paradigm of the infectious process. However, little attention is paid to the unique microecological conditions that are formed in CF respiratory tract. This study aimed to exploring the microecological conditions and to finding out how they may influence the pathogenesis of CF infections. These conditions emerge under the influence of local disruptions in the respiratory functions; inflammatory processes, and complicated relations of the individual microorganisms between each other and between the human bodies as their ecological substrates. As a result, microorganisms that are usually safe for the healthy people become extremely dangerous for CF patients; having adapted to a new ecological niche and having got definite resource advantage, which is attributed to the respiratory tract tissue destruction. Additionally, it is still unknown; how do the anaerobic microbes contribute to CF infections, and whether they collaborate with the traditional CF pathogens or compete with them. In this article, we are analyzing CF respiratory infections from the ecological perspective and proposing in our opinion a more comprehensive picture of their pathogenesis.
{"title":"Complex ecological approach to cystic fibrosis respiratory infections","authors":"Dmitriy V. Alekseev, Artem V. Lyamin, Karim A. Kayumov","doi":"10.21608/nrmj.2023.327188","DOIUrl":"https://doi.org/10.21608/nrmj.2023.327188","url":null,"abstract":"Cystic fibrosis (CF) is one of the most common genetic disorders; resulting in a wide variety of complications, including respiratory infections. Such infections are often ineffectively treated within the framework of a classical paradigm of the infectious process. However, little attention is paid to the unique microecological conditions that are formed in CF respiratory tract. This study aimed to exploring the microecological conditions and to finding out how they may influence the pathogenesis of CF infections. These conditions emerge under the influence of local disruptions in the respiratory functions; inflammatory processes, and complicated relations of the individual microorganisms between each other and between the human bodies as their ecological substrates. As a result, microorganisms that are usually safe for the healthy people become extremely dangerous for CF patients; having adapted to a new ecological niche and having got definite resource advantage, which is attributed to the respiratory tract tissue destruction. Additionally, it is still unknown; how do the anaerobic microbes contribute to CF infections, and whether they collaborate with the traditional CF pathogens or compete with them. In this article, we are analyzing CF respiratory infections from the ecological perspective and proposing in our opinion a more comprehensive picture of their pathogenesis.","PeriodicalId":34593,"journal":{"name":"Novel Research in Microbiology Journal","volume":"56 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139238706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-14DOI: 10.21608/nrmj.2023.330426
Naam Fadhil Abbas Al-Helli, Jehan Abdul Sattar Salman
Biofilm formation by Escherichia coli presents a major challenge in the clinical settings, resulting in persistent infections and treatment failures. These bacterial communities, protected by a matrix, resist antibiotics and immune responses, thus causing a prolonged challenge to treat such infections. Developing effective strategies against E. coli biofilms is crucial for improving the patient outcomes and reducing the burden on the healthcare systems. This study aimed to extract, purify, and characterize mannan from Saccharomyces cerevisiae , then its antibiofilm activity was evaluated against the multi-drug resistant E. coli (MDR-E. coli ) isolates obtained from various clinical sources ( i.e ., urine, stool, wound, and catheter). Using a standardized protocol with slight modifications, the crude mannan extraction yielded 37.6 %, and subsequent purification achieved an efficiency of 99.6 %. Characterization assays of the purified mannan included FT-IR; FE-SEM, carbohydrate content estimation, solubility, and melting point tests, which revealed the presence of α-1,6 and α-1,2 linked sugars; crystalline nature, high porosity (80 %) carbohydrate content, high solubility in water, and a melting point of 248 °C. The purified mannan exhibited a substantial ability to inhibit biofilm formation (37.50 %) and degrade the existing MDR-E. coli biofilms (37.43 %). These findings underscore the potential of S. cerevisiae mannan as an effective antibiofilm agent for the clinical applications. Further exploration and optimization of the mannan's therapeutic potential are essential to fully leverage its efficacy in combating the biofilm-associated infections caused by MDR-E. coli .
{"title":"The antibiofilm activity of purified and characterized mannan from Saccharomyces cerevisiae against multidrug-resistant Escherichia coli","authors":"Naam Fadhil Abbas Al-Helli, Jehan Abdul Sattar Salman","doi":"10.21608/nrmj.2023.330426","DOIUrl":"https://doi.org/10.21608/nrmj.2023.330426","url":null,"abstract":"Biofilm formation by Escherichia coli presents a major challenge in the clinical settings, resulting in persistent infections and treatment failures. These bacterial communities, protected by a matrix, resist antibiotics and immune responses, thus causing a prolonged challenge to treat such infections. Developing effective strategies against E. coli biofilms is crucial for improving the patient outcomes and reducing the burden on the healthcare systems. This study aimed to extract, purify, and characterize mannan from Saccharomyces cerevisiae , then its antibiofilm activity was evaluated against the multi-drug resistant E. coli (MDR-E. coli ) isolates obtained from various clinical sources ( i.e ., urine, stool, wound, and catheter). Using a standardized protocol with slight modifications, the crude mannan extraction yielded 37.6 %, and subsequent purification achieved an efficiency of 99.6 %. Characterization assays of the purified mannan included FT-IR; FE-SEM, carbohydrate content estimation, solubility, and melting point tests, which revealed the presence of α-1,6 and α-1,2 linked sugars; crystalline nature, high porosity (80 %) carbohydrate content, high solubility in water, and a melting point of 248 °C. The purified mannan exhibited a substantial ability to inhibit biofilm formation (37.50 %) and degrade the existing MDR-E. coli biofilms (37.43 %). These findings underscore the potential of S. cerevisiae mannan as an effective antibiofilm agent for the clinical applications. Further exploration and optimization of the mannan's therapeutic potential are essential to fully leverage its efficacy in combating the biofilm-associated infections caused by MDR-E. coli .","PeriodicalId":34593,"journal":{"name":"Novel Research in Microbiology Journal","volume":"59 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139276977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-11-11DOI: 10.21608/nrmj.2023.325660
Taha Chouati, Ounayssa Ayadi, Mohammed Ajdig, Lahcen Ouchari, Bahia Rached, Jamila El Alami, Elmostafa El Fahime
Proteases; especially alkaline proteases, constitute the most used group of enzymes in industry. The wide scope of their application requires varying properties; most commonly stability throughout the conditional changes that would occur during the various industrial processes. This study aimed to identify the potentially interesting bacterial strains obtained from Moroccan extreme environment
{"title":"Quantification of thermo-halotolerant alkaline protease activity derived from Bacillus licheniformis strains isolated from extreme environments in Morocco","authors":"Taha Chouati, Ounayssa Ayadi, Mohammed Ajdig, Lahcen Ouchari, Bahia Rached, Jamila El Alami, Elmostafa El Fahime","doi":"10.21608/nrmj.2023.325660","DOIUrl":"https://doi.org/10.21608/nrmj.2023.325660","url":null,"abstract":"Proteases; especially alkaline proteases, constitute the most used group of enzymes in industry. The wide scope of their application requires varying properties; most commonly stability throughout the conditional changes that would occur during the various industrial processes. This study aimed to identify the potentially interesting bacterial strains obtained from Moroccan extreme environment","PeriodicalId":34593,"journal":{"name":"Novel Research in Microbiology Journal","volume":"22 5","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135086990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}